Cogent Biosciences, Inc. (COGT) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Prev close 32.74 · gapped above the open, then crossed back over prior close. High/low 33.96 at 8:30 am ET, 32.74 at 4:00 pm ET.
Cogent Biosciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
7 readings, 4 filed under bull and 3 under bear. Every figure is ours; the model chose the side.
the bull case· 4
+5.32%
net increase in shares held by the largest reporting managers
13fJun 30 '26326
managers reporting positions in regulatory filings
13fJun 30 '261.14%
share of an ETF's assets held by the largest fund on file
n-portJun 30 '264
funds on file reporting positions in the company
n-portas of Jun 30 '26the bear case· 3
8 of 8
reports in which the move came in under options implied ranges
earnings historyimplied vs realized5 of 22
largest reporting managers that cut their stake in the latest quarter
13fJun 30 '2642
managers whose positions together make up most of reported value
13fJun 30 '26The model filed each reading under bull or bear and wrote its caption; a caption carrying a digit is replaced by our own phrase, so every figure on this zone is ours. Built Sep 16 '26 against the Nov 10 '26 report; rebuilt when that date rolls. Not a forecast, not advice.
326 managers report a position worth $7.6B between them, and 42 of them hold 80% of it.
tall tick = annual report · 1 on record
COGT (Cogent Biosciences, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Of the 6 companies Cogent Biosciences, Inc. moves with most closely, none share its SEC classification.
Measured against 134 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.